# Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Study · id `cardio:ct-nct03860935` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03860935](<https://clinicaltrials.gov/study/NCT03860935>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03860935

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

## Technical summary

Registry record NCT03860935. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-19 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-06-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 632 participants (enrolled count; ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Started: 2019-03-19 (actual) (ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Primary completion: 2023-05-11 (actual) (ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Completion: 2023-05-11 (actual) (ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Results first posted: 2024-06-27 (ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Brazil; Canada; Czechia; Denmark; Greece; Ireland; Israel; Italy; Netherlands; New Zealand; Poland; Portugal; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT03860935, source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03860935-2024-06-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
- Acronym: ATTRibute-CM
- Condition: Amyloidosis
- Condition: Amyloid Cardiomyopathy
- Condition: Transthyretin Amyloidosis
- Condition: Cardiomyopathies
- Condition: Heart Diseases
- Intervention (Drug): acoramidis
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Eidos Therapeutics, a BridgeBio company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Eidos Therapeutics, a BridgeBio company (`cardio:org-eidos-therapeutics-a-bridgebio-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (`cardio:pubmed-38197816`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of in-clinic assessment of 6MWT by conventional method and using wearable sensors for patients with ATTR-CM (`cardio:pubmed-39878480`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (`cardio:pubmed-40074465`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy (`cardio:pubmed-40398971`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy (`cardio:pubmed-40750720`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial (`cardio:pubmed-42525404`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial (`cardio:pubmed-42669902`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4a099f745615b2c928303258f31c28da7aefcafa40aac69c0deb88ad34516fb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
